Physician profile
Justin D Thomas
NPI 1104002195
$8,787.15
in general payments reported to CMS, 2019-2025
31 companies · $2,487 in 2025
The $2,487 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,758 · 2020: $268 · 2021: $1,665 · 2022: $281 · 2023: $1,181 · 2024: $1,147 · 2025: $2,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,124 · Travel and Lodging: $965 · Consulting Fee: $600 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,123.93 |
| Travel and Lodging | $965.13 |
| Consulting Fee | $600.00 |
| Education | $126.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $2,410.81 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $2,106.57 | 2020-2025 | Enhertu, Lynparza |
| Janssen Biotech, INC. | $796.59 | 2022-2025 | Darzalex, Tecvayli, Talvey |
| Ethicon INC. | $694.59 | 2019 | |
| Abbvie INC. | $656.67 | 2024-2025 | |
| Lilly USA, LLC | $252.66 | 2023-2025 | Verzenio, Retevmo, Jaypirca |
| Pfizer INC. | $215.52 | 2023-2025 | |
| Celgene Corporation | $178.78 | 2023-2025 | Reblozyl, Breyanzi |
| Blueprint Medicines Corporation | $135.00 | 2022 | |
| Glaxosmithkline, LLC. | $134.13 | 2022-2025 | Ojjaara |
| Pharmacyclics LLC, An Abbvie Company | $131.69 | 2023 | Imbruvica, Epkinly |
| E.R. Squibb & Sons, L.L.C. | $116.36 | 2023-2024 | Krazati, Sprycel, Opdualag |
| Stemline Therapeutics INC. | $114.01 | 2024-2025 | Orserdu |
| Janssen Scientific Affairs, LLC | $112.26 | 2022-2023 | Darzalex, Tecvayli |
| Aveo Pharmaceuticals, INC. | $109.55 | 2023-2025 | Fotivda |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $77.96 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $72.40 | 2025 | Libtayo |
| Seagen INC. | $64.85 | 2023 | Adcetris |
| Servier Pharmaceuticals LLC | $60.81 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $49.40 | 2025 | |
| Pharming Healthcare, INC. | $47.05 | 2023 | Ruconest |
| Genzyme Corporation | $43.93 | 2023-2024 | |
| Aadi Bioscience, INC. | $40.61 | 2025 | Fyarro |
| Caris Mpi, INC. | $36.15 | 2025 | Mi Cancer Seek |
| Adc Therapeutics America, INC. | $24.13 | 2025 | |
| Tersera Therapeutics LLC | $20.08 | 2025 | Xermelo |
| Acrotech Biopharma INC. | $19.58 | 2024 | Beleodaq |
| Incyte Corporation | $18.70 | 2025 | Monjuvi |
| Recordati_rare_diseases_inc. | $16.09 | 2023 | Sylvant |
| Exelixis INC. | $15.57 | 2024 | |
| Alexion Pharmaceuticals, INC. | $14.65 | 2023 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.